Insulet (PODD) to Release Earnings on Thursday

Insulet (NASDAQ:PODD) is set to post its quarterly earnings results after the market closes on Thursday, May 9th. Analysts expect Insulet to post earnings of $0.39 per share for the quarter. Insulet has set its FY 2024 guidance at EPS and its Q1 2024 guidance at EPS.Persons interested in participating in the company’s earnings conference call can do so using this link.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.73. The firm had revenue of $509.80 million for the quarter, compared to analyst estimates of $461.26 million. Insulet had a return on equity of 32.19% and a net margin of 12.16%. Insulet’s quarterly revenue was up 37.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.55 earnings per share. On average, analysts expect Insulet to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Insulet Trading Up 1.1 %

NASDAQ:PODD opened at $176.40 on Tuesday. The stock has a fifty day moving average price of $169.57 and a two-hundred day moving average price of $181.21. The stock has a market capitalization of $12.35 billion, a price-to-earnings ratio of 60.62, a PEG ratio of 3.14 and a beta of 1.00. The company has a debt-to-equity ratio of 1.86, a quick ratio of 2.62 and a current ratio of 3.51. Insulet has a 1 year low of $125.82 and a 1 year high of $331.65.

Insider Buying and Selling at Insulet

In other Insulet news, Director Shacey Petrovic sold 11,609 shares of Insulet stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total value of $1,891,338.28. Following the completion of the sale, the director now owns 2,567 shares in the company, valued at approximately $418,215.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.47% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Barclays dropped their price target on Insulet from $214.00 to $213.00 and set an “equal weight” rating for the company in a research report on Monday, February 26th. JPMorgan Chase & Co. raised their price target on Insulet from $190.00 to $225.00 and gave the company an “overweight” rating in a research report on Friday, February 23rd. Piper Sandler dropped their price target on Insulet from $250.00 to $230.00 and set an “overweight” rating for the company in a research report on Friday, February 23rd. Finally, Stifel Nicolaus raised their price target on Insulet from $163.00 to $208.00 and gave the company a “hold” rating in a research report on Monday, February 5th. Four research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, Insulet has an average rating of “Moderate Buy” and an average target price of $243.21.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.